Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
April 16, 2024 20:01 ET
|
Acrivon Therapeutics, Inc
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
Millicom’s Nomination Committee’s proposal for Board of Directors
April 16, 2024 20:00 ET
|
Millicom International Cellular S.A.
Millicom’s Nomination Committee’s proposal for Board of Directors Luxembourg, April 17, 2024 – In advance of the Annual General Meeting of shareholders (“AGM”) of Millicom International Cellular...
Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders
April 16, 2024 20:00 ET
|
Millicom International Cellular S.A.
Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders MILLICOM INTERNATIONAL CELLULAR S.A.Registered Address: 2, Rue du Fort BourbonL-1249 Luxembourg, Grand...
Beam Global Reports Record Year End 2023 Operating Results
April 16, 2024 19:02 ET
|
Beam Global
Beam Global Reports Record Year End 2023 Operating Results
James River Completes Sale of Casualty Reinsurance Business to Fleming Holdings
April 16, 2024 18:35 ET
|
James River Group Holdings, Ltd.
PEMBROKE, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- James River Group Holdings, Ltd. (“James River” or the “Company”) (NASDAQ: JRVR) today announced that Fleming Intermediate Holdings (“Fleming”)...
Beam Global to Release 2023 Operating Results, Conference Call Scheduled for April 17, 2024 at 4:30 p.m. ET
April 16, 2024 18:34 ET
|
Beam Global
Beam Global to Release 2023 Operating Results, Conference Call Scheduled for April 17, 2024 at 4:30 p.m. ET
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 16, 2024 18:21 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at...
Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn) líftæknilyfjahliðstæðu við Stelara
April 16, 2024 17:30 ET
|
Alvotech
Markaðsleyfið er fyrir notkun lyfsins til meðferðar bæði á fullorðnum og börnum Þetta er önnur líftæknilyfjahliðstæða Alvotech sem hlýtur markaðsleyfi í Bandaríkjunum Gert er ráð fyrir að Selarsdi...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024 17:30 ET
|
Alvotech
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024 17:30 ET
|
Alvotech
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the...